Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiphospholipid cofactor.

A E Gharavi1

  • 1Antiphospholipid Research Laboratory, Hospital for Special Surgery, Cornell University Medical Center, New York, N.Y. 10021.

Stroke
|February 1, 1992
PubMed
Summary
This summary is machine-generated.

Beta 2-glycoprotein I acts as a cofactor, enhancing antiphospholipid antibody binding to phospholipids. This confirms its crucial role in antiphospholipid syndrome, impacting autoimmune antibody interactions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intrauterine fetal death in mice caused by cytomegalovirus-derived peptide induced aPL antibodies.

Lupus·2004
Same author

The molecular basis of antiphospholipid syndrome.

Lupus·2003
Same author

Infections and antiphospholipid antibodies.

Le Journal medical libanais. The Lebanese medical journal·2002
Same author

Origin of antiphospholipid antibodies.

Rheumatic diseases clinics of North America·2001
Same author

International classification criteria for antiphospholipid syndrome: synopsis of a post-conference workshop held at the Ninth International (Tours) aPL Symposium.

Lupus·2001
Same author

Anticardiolipin antibodies: importance, controversies, discrepancies; the need for guidelines and calibrators.

Clinical and experimental rheumatology·2001
Same journal

Management of Patients at Risk of Ischemic Stroke With Left Ventricular Systolic Dysfunction in the Absence of Intracardiac Thrombus: A Scientific Statement From the American Heart Association.

Stroke·2026
Same journal

Update on Rehabilitation After Stroke: Global Changes and the Continued Importance of Therapy Intensity, Dose, and Timing.

Stroke·2026
Same journal

ENTF Neuromodulation Yields Reduced Disability After Stroke: An Individual Participant-Level Data Meta-Analysis.

Stroke·2026
Same journal

Menopause and Its Implications for Stroke in Women.

Stroke·2026
Same journal

Physician Approaches to Determining Goals of Stroke Care for Patients Living With Disability or Dementia: Results from the SEED Mixed-Methods Study.

Stroke·2026
Same journal

Aspirin for Stroke Primary Prevention: A Step Toward Genetic-Driven Personalized Medicine.

Stroke·2026
See all related articles

Area of Science:

  • Immunology
  • Biochemistry
  • Hematology

Background:

  • Antiphospholipid antibodies (aPL) are crucial in antiphospholipid syndrome (APS).
  • Beta 2-glycoprotein I (β2GPI) is a plasma protein that binds phospholipids and is implicated in aPL-phospholipid interactions.
  • The precise mechanism of aPL binding to β2GPI and phospholipids remains unclear.

Purpose of the Study:

  • To investigate the role of β2GPI as a cofactor in the binding of aPL to phospholipids.
  • To clarify the interaction between aPL, β2GPI, and phospholipids.

Main Methods:

  • Enzyme-linked immunosorbent assays (ELISAs) were employed.
  • Isolated β2GPI and purified IgG and IgM aPL from APS patients were used.
  • The binding of aPL to β2GPI and phospholipids, with and without β2GPI, was assessed.

Related Experiment Videos

Main Results:

  • IgG aPL did not bind to β2GPI alone when immobilized on assay plates.
  • β2GPI significantly enhanced the binding of both IgG and IgM aPL to phospholipids.
  • The cofactor effect of β2GPI varied among patients, with IgM aPL showing higher cofactor requirement.

Conclusions:

  • β2GPI is essential as a cofactor for the binding of autoimmune aPL to phospholipids.
  • The findings support the model where β2GPI facilitates aPL recognition of phospholipid antigens.
  • This clarifies the immunological mechanism underlying antiphospholipid syndrome pathogenesis.